Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma
(2018) In Journal of Translational Medicine 16(1).- Abstract
Background: Periampullary adenocarcinomas, including pancreatic cancer, are a heterogeneous group of tumors with poor prognosis, where classification into intestinal type (I-type) or pancreatobiliary type (PB-type) is a relevant prognostic factor. The clinical significance of deficient mismatch repair (dMMR) in periampullary adenocarcinoma is comparatively unexplored. Herein, we examined the associations of MMR immunophenotype with long-term survival in patients with resected periampullary adenocarcinoma, with particular reference to morphology and adjuvant treatment response. Methods: MMR protein expression was assessed by immunohistochemistry on tissue microarrays with primary tumors from a retrospective cohort of 175 patients with... (More)
Background: Periampullary adenocarcinomas, including pancreatic cancer, are a heterogeneous group of tumors with poor prognosis, where classification into intestinal type (I-type) or pancreatobiliary type (PB-type) is a relevant prognostic factor. The clinical significance of deficient mismatch repair (dMMR) in periampullary adenocarcinoma is comparatively unexplored. Herein, we examined the associations of MMR immunophenotype with long-term survival in patients with resected periampullary adenocarcinoma, with particular reference to morphology and adjuvant treatment response. Methods: MMR protein expression was assessed by immunohistochemistry on tissue microarrays with primary tumors from a retrospective cohort of 175 patients with periampullary adenocarcinoma treated with pancreaticoduodenectomy during 2001-2011 in Malmö and Lund University Hospitals, Sweden. Cox proportional hazards models were applied to calculate hazard ratios (HR) and 95% confidence intervals (CI). Results: After a mean follow-up of 46.5 (1.9-185.1) months, 35 patients (20.3%) were alive, 24 with I-type and 11 with PB-type tumors. MMR protein expression could be evaluated in 172 cases, in which dMMR was denoted in 20 (11.6%) cases, 13/63 (20.6%) in I-type and 7/109 (6.4%) in PB-type tumors. dMMR was associated with a significantly prolonged overall survival in the entire cohort (HR=0.28, 95% CI 0.13-0.57), and in I-type tumors (HR=0.20, 95% CI 0.06-0.68), however not independent of conventional prognostic factors. In PB-type tumors, dMMR was not prognostic, but there was a significant negative interaction between dMMR and adjuvant treatment (pinteraction=0.015). Conclusions: dMMR is more frequent in I-type compared to PB-type periampullary adenocarcinoma, and is a prognostic factor for long-term survival only in the former. The finding of the small number of PB-type tumors with dMMR potentially lacking benefit from adjuvant chemotherapy is however noteworthy and merits further validation.
(Less)
- author
- Heby, Margareta LU ; Lundgren, Sebastian LU ; Nodin, Björn LU ; Elebro, Jacob LU ; Eberhard, Jakob LU and Jirström, Karin LU
- organization
- publishing date
- 2018-03-14
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adjuvant therapy, Immunohistochemistry, MMR, Periampullary adenocarcinoma, TMA
- in
- Journal of Translational Medicine
- volume
- 16
- issue
- 1
- article number
- 66
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:29540182
- scopus:85043767594
- ISSN
- 1479-5876
- DOI
- 10.1186/s12967-018-1444-4
- language
- English
- LU publication?
- yes
- id
- 2e81a9aa-4767-47cc-989c-da72db704204
- date added to LUP
- 2018-03-26 13:48:27
- date last changed
- 2024-10-14 23:54:20
@article{2e81a9aa-4767-47cc-989c-da72db704204, abstract = {{<p>Background: Periampullary adenocarcinomas, including pancreatic cancer, are a heterogeneous group of tumors with poor prognosis, where classification into intestinal type (I-type) or pancreatobiliary type (PB-type) is a relevant prognostic factor. The clinical significance of deficient mismatch repair (dMMR) in periampullary adenocarcinoma is comparatively unexplored. Herein, we examined the associations of MMR immunophenotype with long-term survival in patients with resected periampullary adenocarcinoma, with particular reference to morphology and adjuvant treatment response. Methods: MMR protein expression was assessed by immunohistochemistry on tissue microarrays with primary tumors from a retrospective cohort of 175 patients with periampullary adenocarcinoma treated with pancreaticoduodenectomy during 2001-2011 in Malmö and Lund University Hospitals, Sweden. Cox proportional hazards models were applied to calculate hazard ratios (HR) and 95% confidence intervals (CI). Results: After a mean follow-up of 46.5 (1.9-185.1) months, 35 patients (20.3%) were alive, 24 with I-type and 11 with PB-type tumors. MMR protein expression could be evaluated in 172 cases, in which dMMR was denoted in 20 (11.6%) cases, 13/63 (20.6%) in I-type and 7/109 (6.4%) in PB-type tumors. dMMR was associated with a significantly prolonged overall survival in the entire cohort (HR=0.28, 95% CI 0.13-0.57), and in I-type tumors (HR=0.20, 95% CI 0.06-0.68), however not independent of conventional prognostic factors. In PB-type tumors, dMMR was not prognostic, but there was a significant negative interaction between dMMR and adjuvant treatment (p<sub>interaction</sub>=0.015). Conclusions: dMMR is more frequent in I-type compared to PB-type periampullary adenocarcinoma, and is a prognostic factor for long-term survival only in the former. The finding of the small number of PB-type tumors with dMMR potentially lacking benefit from adjuvant chemotherapy is however noteworthy and merits further validation.</p>}}, author = {{Heby, Margareta and Lundgren, Sebastian and Nodin, Björn and Elebro, Jacob and Eberhard, Jakob and Jirström, Karin}}, issn = {{1479-5876}}, keywords = {{Adjuvant therapy; Immunohistochemistry; MMR; Periampullary adenocarcinoma; TMA}}, language = {{eng}}, month = {{03}}, number = {{1}}, publisher = {{BioMed Central (BMC)}}, series = {{Journal of Translational Medicine}}, title = {{Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma}}, url = {{http://dx.doi.org/10.1186/s12967-018-1444-4}}, doi = {{10.1186/s12967-018-1444-4}}, volume = {{16}}, year = {{2018}}, }